Each of these measurements would be performed regardless of randomization. Detailed descriptions of these assays/tests are described in Section 4.4.4 – 4.4.9. Dimer and ELISPOT measurements may be performed prior to initiating the vaccination series as well as prior to the fourth inoculation, and at one month after completion of the primary series. Additionally, these assays may be performed pre- and post- each booster and at completion of the study. Alternatively, these assayed timepoints may also be performed all at once on frozen cells and may be collected from selected sites only. DTH reactions will be measured prior to initiation of the vaccination series, 3-4 weeks after completion of the primary series, and 3-4 weeks after the second and fourth boosters (Appendix A). Immunologic responses in the patients randomized to receive Herceptin + E75/GM-CSF will be compared to the cohort of patients randomized to receive Herceptin + GM-CSF alone. Cardiac toxicity of combination therapy will also be assessed. Each patient, regardless of randomization, will undergo cardiac assessment (ejection fraction) at baseline (MUGA preferred, ECHO allowed, consistency required) and at 3, 6, 12, and 24 months. Cardiac assessment will continue every six months if a patient experiences a greater than 10% reduction from baseline for the duration of the trial or until resolution. 3.3.3 Ancillary Safety Outcome Measures Standard local and systemic toxicities will be collected and graded per the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 graded toxicity scale (Appendix B). For both the regular inoculations and the booster inoculations, patients will be monitored for 30 minutes after the inoculation with vital signs taken as needed. Patients will either return to the vaccine clinic at their respective study site or be contacted by phone for questioning regarding any systemic and local toxicity, during the initial 48-72 hours after inoculation. If they return to their study site, the local reaction at the inoculation sites will be examined and measured. For patients that do not return to the study site, a tool will be given and instructions provided to measure the local reaction. Serious adverse events will be reported as described in Section 5. 3.4 SAFETY PLAN Patients will be evaluated at each study visit for the duration of their participation in the study (Appendix C.1, C.2).